[Indications of direct oral anticoagulant rivaroxaban in cardiovascular disease].

Rivaroxaban, an oral direct anticoagulant that is a selective inhibitor of Xa factor, was commercialized in Belgium in 2009 with as unique reimbursed indication the prevention of thromboembolic events before a programmed hip or knee prosthesis. Since that time, both the efficacy and safety of rivaroxaban have been validated in a variety of indications : prevention and treatment of venous thromboembolic disease with or without pulmonary embolism, non valvular atrial fibrillation, symptomatic coronary disease and peripheral arteriopathy. Different presentations are currently available from 2.5 mg to 20 mg to allow the practitioner adjust the dosage of rivaroxaban to the specific indication (for instance, in patents with symptomatic atheromatous cardiovascular disease, 2 x 2.5 mg/day in combination with a antiplatelet agent).